Breast Cancer
Conference Coverage
KATHERINE: T-DM1 doubles HER2-positive invasive disease-free survival
SAN ANTONIO – For the primary endpoint of invasive disease-free survival, T-DM1 was associated with a hazard ratio of 0.50.
Conference Coverage
SABCS 2018: Can CTCs determine treatment for advanced breast cancer?
Results of the phase 3 STIC CTC trial will address the clinical utility of circulating tumor cells in choosing treatment approaches.
Conference Coverage
SABCS 2018: PHARE, KATHERINE, and KATE2 in HER2+ breast cancer
Studies in HER2+ breast cancer to be presented at SABCS include a comparison of 6 vs. 12 months of trastuzumab, T-DM1 vs. trastuzumab following...
Conference Coverage
SABCS 2018: Further analysis on IMpassion130 for mTNBC
Investigators presented results of the phase 3 IMpassion130...
From the Journals
SRS beats surgery in early control of brain mets, advantage fades with time
Patients undergoing complete surgical resection for brain mets were at much higher risk of local recurrence than patients.
From the Journals
Circulating tumor DNA identified by fragment size
Circulating tumor DNA in plasma is more likely to be within certain fragment size ranges, which could enable its detection and use in cancer...
Conference Coverage
Nipple-sparing mastectomy safe in older patients
BOSTON – No prior studies had been done specifically to evaluate nipple-sparing mastectomies in older breast cancer patients.
News
FDA approves second pegfilgrastim biosimilar
Pegfilgrastim-cbqv, previously known as CHS-1701, will be marketed as Udenyca by Coherus BioSciences.
From the Journals
Use of topical agents before RT may be safe
Using preclinical models, investigators found that when common topical agents were applied at a thickness of less than 2 mm, negligible effects on...
Conference Coverage
Breast cancer in men comparable with women, gonadal therapy debated
MUNICH – Data from a large retrospective study of metastatic breast cancer indicates that, in general, men and women received similar treatments...
Conference Coverage
SOLAR-1 shines light on PI3K in breast cancer
MUNICH – The selective PI3K inhibitor added to fulvestrant extended progression-free survival in breast cancer patients with PIK3CA mutations.